CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

BioSpace
Original article

Sanofi pays Regeneron $1B upfront to continue search for Dupixent successor

PartnershipDupixentPositive
AI Analysis

Summary

Sanofi will pay Regeneron $1 billion upfront to continue development of a successor to the blockbuster drug Dupixent as the companies prepare for its looming loss of exclusivity.

Importance:6/10
Sentiment:
0.30
partnershippaymentdupixentdrug developmentexclusivity loss
Related Companies

Read the original article

Published by BioSpace on October 1, 2026 12:55 PM

Read Original